(精选)Facts about Antibiotics教学课件.pptVIP

下载本文档

1
0
约2.62万字
约 43页
2018-03-21 发布于天津
举报
版权申诉

(精选)Facts about Antibiotics教学课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

演示文稿演讲PPT学习教学课件医学文件教学培训课件

AUC/MIC90 Ratio of Major FQ for S. pneumoniae FQ Prescription per Capita and Frequency of Pneumococci with Reduced Susceptibility to FQs in Canada According to Patient’s Age (Bars) Treatment for 7 to 14 days ?2 days ?2 days Newly Hospitalized CAP Patients (?18 years) Gatifloxacin IV 400 mg QD n=141 Gatifloxacin PO 400 mg QD Ceftriaxone IV 1 or 2 g (32%) QD ± Erythromycin IV 0.5 or 1 g (39%) q6h n=142 Clarithromycin PO 500 mg BID Fogarty C et al. J Respir Dis. 1999;20(suppl 11):S60-S69. Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information. Gatifloxacin vs Ceftriaxone ± Macrolide in Hospitalized CAP Patients Gatifloxacin vs Ceftriaxone ± Macrolide* in CAP: Clinical and Bacteriologic Response *Macrolides were erythromycin IV and clarithromycin PO step-down.?No. cured/total of clinically evaluable patients; ?No. eradicated/total of microbiologically evaluable patients. NSD=not statistically different Fogarty C et al. J Respir Dis. 1999;20(suppl 11):S60-S69. Gatifloxacin efficacy rates in CAP from clinical trials used as a basis for approval—up to 90% Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information. 97 97 90 92 Gatifloxacin Ceftriaxone ± erythromycin/clarithromycin Clinical Cure? Microbiologic Eradication? 0 70 80 90 100 96/99 96/106 69/71 73/79 Patients with Cure or Eradication (%) NSD NSD *Macrolides were erythromycin IV and clarithromycin PO step-down; ?ATS severity scores; ?No. cured/total of clinically evaluable patients. NSD=not statistically different Niederman MS et al. Am Rev Respir Dis. 1993;148:1418-1426; Fogarty C et al. J Respir Dis. 1999; 20(suppl 11):S60-S69. Gatifloxacin efficacy rates in CAP from clinical trials used as a basis for approval—up to 90% Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information. Gatifloxacin vs Ceftriaxone ± Macrolide* in CAP: Clinical Response by Pneumonia Severity? Gatifloxacin Ceftriaxone ± erythromycin/clari